Astria Therapeutics, Inc., a biopharmaceutical company, engages in developing therapies for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-021, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development stage for the treatment of hereditary angioedema, a rare genetic disorder causing swelling in the face, limbs, abdomen, and airway. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts. The company trades on NGM exchange. The company headquarter is located in Boston, United States. The company was established in the 2008.

TickerATXS
Long NameAstria Therapeutics, Inc.
Short NameAstria Therapeutics, Inc.